{"id":3000,"date":"2026-11-10T06:26:00","date_gmt":"2026-11-10T06:26:00","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-11-10T18:42:25","modified_gmt":"2026-11-10T18:42:25","slug":"epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut","status":"publish","type":"post","link":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/","title":{"rendered":"Epitopea annonce l&#8217;administration de la premi\u00e8re dose \u00e0 une patiente dans le cadre de l&#8217;essai clinique OVACT de phase 1\/1b portant sur le CryptiVaxTM-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CAMBRIDGE, ROYAUME-UNI et MONTR\u00c9AL, CANADA, le 9 novembre 2026<\/strong> \u2013 Epitopea, une soci\u00e9t\u00e9 de biotechnologie au stade clinique d\u00e9veloppant des vaccins anticanc\u00e9reux pr\u00eats \u00e0 l\u2019emploi et durables \u00e0 base d\u2019ARN, a annonc\u00e9 aujourd\u2019hui que la premi\u00e8re patiente avait re\u00e7u avec succ\u00e8s son traitement dans le cadre d\u2019OVACT, son premier essai clinique de phase 1\/1b chez les humains \u00e9valuant son programme phare, CryptiVax\u2122-1001, ciblant le cancer de l\u2019ovaire s\u00e9reux de haut grade (HGSOC) avanc\u00e9.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07665515\" target=\"_blank\" rel=\"noopener\">OVACT<\/a> est un essai de phase 1\/1b \u00e0 escalade de dose con\u00e7u pour \u00e9valuer la s\u00e9curit\u00e9, la tol\u00e9rance, l\u2019immunog\u00e9nicit\u00e9 et l\u2019activit\u00e9 clinique pr\u00e9coce de CryptiVax\u2122-1001 chez des patientes atteintes d\u2019un HGSOC avanc\u00e9 HRP+\/BRCA de type sauvage. Jusqu\u2019\u00e0 30 femmes seront recrut\u00e9es dans le cadre de cet essai dans un maximum de 10 centres cliniques de r\u00e9f\u00e9rence au Royaume-Uni.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le HGSOC reste l\u2019une des tumeurs solides les plus difficiles \u00e0 traiter, environ 80 % des patientes pr\u00e9sentant une maladie avanc\u00e9e ou m\u00e9tastatique. Si la plupart des femmes r\u00e9pondent \u00e0 une chimioth\u00e9rapie de premi\u00e8re ligne \u00e0 base de platine, presque toutes finissent par faire une rechute et d\u00e9veloppent une maladie r\u00e9sistante au platine. Les options de traitement d\u2019entretien existantes ne sont efficaces que chez la moiti\u00e9 des patientes atteintes d\u2019un cancer de l\u2019ovaire et laissent un vide th\u00e9rapeutique important chez les patientes HRP+\/BRCA de type sauvage.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le Dr Klaus Edvardsen, MD, PhD, Chef de la direction m\u00e9dical d\u2019Epitopea, a d\u00e9clar\u00e9 : \u00ab Le HGSOC est le sous-type de cancer de l\u2019ovaire le plus courant et le plus agressif. Le traitement de la premi\u00e8re patiente avec CryptiVax\u2122-1001 dans le cadre de notre essai OVACT de phase 1\/1b consacr\u00e9 au HGSOC constitue une \u00e9tape majeure pour Epitopea. L\u2019approche d\u2019Epitopea cible un r\u00e9pertoire novateur d\u2019antig\u00e8nes sp\u00e9cifiques \u00e0 la tumeur, s\u00e9lectionn\u00e9s pour offrir un b\u00e9n\u00e9fice plus large aux patientes. Nous sommes motiv\u00e9s par la possibilit\u00e9 d\u2019offrir des options th\u00e9rapeutiques significatives et durables \u00e0 cette population de patientes mal prise en charge. \u00bb<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La professeure Susana Banerjee (MBBS, MA, PhD, FRCP), chercheuse principale de l&#8217;essai OVACT men\u00e9 par Epitopea, oncologue m\u00e9dicale consultante et responsable de la recherche au sein de l&#8217;unit\u00e9 de gyn\u00e9cologie du <a href=\"https:\/\/www.royalmarsden.nhs.uk\/\" target=\"_blank\" rel=\"noopener\">Royal Marsden<\/a> NHS Foundation Trust, a d\u00e9clar\u00e9 : \u00ab C\u2019est passionnant de pouvoir proposer aux patientes la possibilit\u00e9 de participer \u00e0 l\u2019essai OVACT et je suis ravie que nous ayons d\u00e9j\u00e0 commenc\u00e9 \u00e0 traiter la premi\u00e8re patiente. Le vaccin CryptiVaxTM-1001 a le potentiel de prolonger de mani\u00e8re significative la r\u00e9mission chez les femmes pour lesquelles les traitements d\u2019entretien actuellement disponibles n\u2019apportent qu\u2019un b\u00e9n\u00e9fice durable limit\u00e9. \u00bb<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FIN<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c0 propos d\u2019Epitopea<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Epitopea est une au stade clinique soci\u00e9t\u00e9 sp\u00e9cialis\u00e9e dans l\u2019immunoth\u00e9rapie anticanc\u00e9reuse qui d\u00e9veloppe des immunoth\u00e9rapies \u00e0 base d\u2019ARN, accessibles et pr\u00eates \u00e0 l\u2019emploi, destin\u00e9es aux tumeurs solides difficiles \u00e0 traiter.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le pipeline d\u2019Epitopea s\u2019appuie sur CryptoMap<sup>TM<\/sup> , un moteur de d\u00e9couverte propri\u00e9taire qui qui identifie de mani\u00e8re empirique les antig\u00e8nes pr\u00e9sent\u00e9s par la tumeur issus du \u00ab g\u00e9nome obscur \u00bb, une source jusqu\u2019alors inaccessible de nouvelles cibles sp\u00e9cifiques aux tumeurs. Ces antig\u00e8nes, appel\u00e9s Cryptigens<sup>TM<\/sup>, pr\u00e9sentent un<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">degr\u00e9 \u00e9lev\u00e9 de partage entre les patients, ce qui permet le d\u00e9veloppement de v\u00e9ritables immunoth\u00e9rapies \u00e0 ARNm pr\u00eates \u00e0 l\u2019emploi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le principal candidat-m\u00e9dicament de la soci\u00e9t\u00e9, CryptiVax\u2122-1001, fait actuellement l\u2019objet de l\u2019essai clinique de phase 1\/1b multicentrique OVACT, consacr\u00e9 au cancer de l\u2019ovaire s\u00e9reux de haut grade. Il est con\u00e7u pour induire des r\u00e9ponses immunitaires cibl\u00e9es \u00e0 l\u2019aide d\u2019un ensemble d\u2019antig\u00e8nes sp\u00e9cifiques \u00e0 la tumeur, s\u00e9lectionn\u00e9s pour leur immunog\u00e9nicit\u00e9 et leur large couverture des patientes. De nombreuses patientes atteintes de cancers avanc\u00e9s, notamment celles souffrant d\u2019un cancer de l\u2019ovaire s\u00e9reux de haut grade, disposent d\u2019options th\u00e9rapeutiques limit\u00e9es offrant des r\u00e9ponses durables, et peu de traitements efficaces sont disponibles en dehors des populations s\u00e9lectionn\u00e9es sur la base de biomarqueurs. Epitopea entend r\u00e9pondre \u00e0 ce besoin non satisfait consid\u00e9rable gr\u00e2ce \u00e0 des immunoth\u00e9rapies \u00e0 base d&#8217;ARNm, \u00e0 large spectre d&#8217;application et ciblant sp\u00e9cifiquement les tumeurs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Soutenue par des investisseurs de premier plan dans le domaine des sciences de la vie, Epitopea op\u00e8re depuis Cambridge, au Royaume-Uni, et Montr\u00e9al, au Canada. Pour plus d\u2019informations, rendez-vous sur <a href=\"https:\/\/www.epitopea.com\/\">www.epitopea.com<\/a> et suivez l\u2019entreprise sur <a href=\"https:\/\/www.linkedin.com\/company\/epitopea\/\" target=\"_blank\" rel=\"noopener\">LinkedIn<\/a>.<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-794e3cfa wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/admarebio.com\/fr\/developper-des-compagnies\/portefeuille\/\">D\u00e9couvrir notre portefeuille de companies portfolio <\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, ROYAUME-UNI et MONTR\u00c9AL, CANADA, le 9 novembre 2026 \u2013 Epitopea, une soci\u00e9t\u00e9 de biotechnologie au stade clinique d\u00e9veloppant des vaccins anticanc\u00e9reux pr\u00eats \u00e0 l\u2019emploi et durables \u00e0 base d\u2019ARN, [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":3012,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"company":[108],"class_list":["post-3000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-des-compagnies-du-portefeuille"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Epitopea annonce l&#039;administration de la premi\u00e8re dose \u00e0 une patiente dans le cadre de l&#039;essai clinique OVACT de phase 1\/1b portant sur le CryptiVaxTM-1001 dans le cancer de l&#039;ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epitopea annonce l&#039;administration de la premi\u00e8re dose \u00e0 une patiente dans le cadre de l&#039;essai clinique OVACT de phase 1\/1b portant sur le CryptiVaxTM-1001 dans le cancer de l&#039;ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, ROYAUME-UNI et MONTR\u00c9AL, CANADA, le 9 novembre 2026 \u2013 Epitopea, une soci\u00e9t\u00e9 de biotechnologie au stade clinique d\u00e9veloppant des vaccins anticanc\u00e9reux pr\u00eats \u00e0 l\u2019emploi et durables \u00e0 base d\u2019ARN, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-10T06:26:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-10T18:42:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Alexis Bouffioux\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis Bouffioux\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/\"},\"author\":{\"name\":\"Alexis Bouffioux\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/87e6ba6ef08826d003854731e1971add\"},\"headline\":\"Epitopea annonce l&#8217;administration de la premi\u00e8re dose \u00e0 une patiente dans le cadre de l&#8217;essai clinique OVACT de phase 1\\\/1b portant sur le CryptiVaxTM-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9\",\"datePublished\":\"2026-11-10T06:26:00+00:00\",\"dateModified\":\"2026-11-10T18:42:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/\"},\"wordCount\":832,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/partnership-6-3.png\",\"articleSection\":[\"Actualit\u00e9s des compagnies du portefeuille\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/\",\"name\":\"Epitopea annonce l'administration de la premi\u00e8re dose \u00e0 une patiente dans le cadre de l'essai clinique OVACT de phase 1\\\/1b portant sur le CryptiVaxTM-1001 dans le cancer de l'ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/partnership-6-3.png\",\"datePublished\":\"2026-11-10T06:26:00+00:00\",\"dateModified\":\"2026-11-10T18:42:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/partnership-6-3.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/partnership-6-3.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nouvelles et \u00e9v\u00e9nements\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s et perspectives\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Epitopea annonce l&#8217;administration de la premi\u00e8re dose \u00e0 une patiente dans le cadre de l&#8217;essai clinique OVACT de phase 1\\\/1b portant sur le CryptiVaxTM-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/87e6ba6ef08826d003854731e1971add\",\"name\":\"Alexis Bouffioux\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Epitopea annonce l'administration de la premi\u00e8re dose \u00e0 une patiente dans le cadre de l'essai clinique OVACT de phase 1\/1b portant sur le CryptiVaxTM-1001 dans le cancer de l'ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/","og_locale":"fr_FR","og_type":"article","og_title":"Epitopea annonce l'administration de la premi\u00e8re dose \u00e0 une patiente dans le cadre de l'essai clinique OVACT de phase 1\/1b portant sur le CryptiVaxTM-1001 dans le cancer de l'ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare","og_description":"CAMBRIDGE, ROYAUME-UNI et MONTR\u00c9AL, CANADA, le 9 novembre 2026 \u2013 Epitopea, une soci\u00e9t\u00e9 de biotechnologie au stade clinique d\u00e9veloppant des vaccins anticanc\u00e9reux pr\u00eats \u00e0 l\u2019emploi et durables \u00e0 base d\u2019ARN, [&hellip;]","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/","og_site_name":"adMare","article_published_time":"2026-11-10T06:26:00+00:00","article_modified_time":"2026-11-10T18:42:25+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-3.png","type":"image\/png"}],"author":"Alexis Bouffioux","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Alexis Bouffioux","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/"},"author":{"name":"Alexis Bouffioux","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/87e6ba6ef08826d003854731e1971add"},"headline":"Epitopea annonce l&#8217;administration de la premi\u00e8re dose \u00e0 une patiente dans le cadre de l&#8217;essai clinique OVACT de phase 1\/1b portant sur le CryptiVaxTM-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9","datePublished":"2026-11-10T06:26:00+00:00","dateModified":"2026-11-10T18:42:25+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/"},"wordCount":832,"publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-3.png","articleSection":["Actualit\u00e9s des compagnies du portefeuille"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/","name":"Epitopea annonce l'administration de la premi\u00e8re dose \u00e0 une patiente dans le cadre de l'essai clinique OVACT de phase 1\/1b portant sur le CryptiVaxTM-1001 dans le cancer de l'ovaire s\u00e9reux de haut grade avanc\u00e9 | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-3.png","datePublished":"2026-11-10T06:26:00+00:00","dateModified":"2026-11-10T18:42:25+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-3.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/11\/partnership-6-3.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/epitopea-annonce-ladministration-de-la-premiere-dose-a-une-patiente-dans-le-cadre-de-lessai-clinique-ovact-de-phase-1-1b-portant-sur-le-cryptivaxtm-1001-dans-le-cancer-de-lovaire-sereux-de-haut\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Nouvelles et \u00e9v\u00e9nements","item":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s et perspectives","item":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/"},{"@type":"ListItem","position":4,"name":"Epitopea annonce l&#8217;administration de la premi\u00e8re dose \u00e0 une patiente dans le cadre de l&#8217;essai clinique OVACT de phase 1\/1b portant sur le CryptiVaxTM-1001 dans le cancer de l&#8217;ovaire s\u00e9reux de haut grade avanc\u00e9"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/87e6ba6ef08826d003854731e1971add","name":"Alexis Bouffioux","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/3000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=3000"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/3000\/revisions"}],"predecessor-version":[{"id":3001,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/3000\/revisions\/3001"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media\/3012"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=3000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/categories?post=3000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/tags?post=3000"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/company?post=3000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}